Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danvatirsen in Malignant Ascites
NCT02417753Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2015
- Primary completion
- Apr 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of danvatirsen in ovarian cancer, gastrointestinal cancer, sponsored by National Cancer Institute. Started Apr 2015; status: terminated.
02
Drugs
danvatirsen
03
Conditions
ovarian cancergastrointestinal cancer
Beyond the preview
Go deeper on NCT02417753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02417753.